Related Blog Posts
Small addition to cancer drug may make big difference
1 day ago ago from insider - UF College of Medicine News Resource - University of Florida
University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chem Satya Narayan, a professor of anatomy and cell biology at the College of Medicine and a member of the UF Shands Cancer Center. otherapy drug to achieve even better results against colon cancer cells. More research is needed before the therapy can be tested in patients, but the discovery in ...
Related contentOncothyreon Partner Starts New Lung Cancer Trial, Prompts Takeover Scuttle
3 hours ago ago from Xconomy
Biotech , cancer , vaccines Luke Timmerman wrote: Seattle-based Oncothyreon (NASDAQ: ONTY ), the developer of a vaccine treatment to stimulate the immune system against cancer cells, said today that its partner has started another pivotal trial of the product. Germany-based Merck KGaA has begun a trial that will include 420 patients in Asia who will get the vaccine, dubbed Stimuvax, or a placebo for non-small cell lung cancer. This ...
Related contentBiomoda Partners with Christiana Care to Complete Pilot Study on Cancer Diagnostic
1 hour, 17 minutes ago ago from BabyBullTwits
In a press release this morning, Biomoda, Inc. (OTCBB: BMOD) announced that The Helen F. Graham Cancer Center associated with Christiana Care Health System, a screening site for the International Early Lung Cancer Program (I-ELCAP), will recruit a cohort of patients diagnosed with lung cancer to participate in the final stage of the Phase II pilot study of the investigational CyPath® assay, an early-stage diagnostic test for lung cancer. ...
Related contentRelated News
Cancer guidelines anger survivors | detnews.com | The Detroit News
13 hours ago ago from Detroit News
Archive: Thu | Fri | Sat | Sun | Mon | Tue | Wed | Today Last Updated: December 10. 2009 8:57AM Cancer guidelines anger survivors Advocates slam proposals for later, fewer screenings Kim Kozlowski / The Detroit News After a decade of breast ...
Related contentImmunogen reports positive breast cancer drug data
21 hours ago ago from Good News Now
NEW YORK -Immunogen Inc. said Wednesday its developing cancer treatment T-DM1 prompted a 32.7 percent response rate in a midstage study on breast cancer patients, pushing shares higher. The stock jumped 72 cents, or 8.8 percent, to close at $8.89, as investors viewed the results as positive for the drug candidate's regulatory prospects. The company will present the clinical data at the 32nd Annual San Antonio Breast Cancer Symposium on ...
Related contentRelated Videos
Nothing to see... move along.
